The market reaction to the news of this deal seems to suggest that we caught it unawares, even though I hinted at it in the Annual Report.
Maybe there was even a bit of ‘why bother’, since we had so obviously nailed our future to that of super-benzopyran drugs and their ability to destroy cancer stem cells. I can hear the questions now:
“Didn’t they have enough on their plate already?”
“Does this mean that the super-benzopyran drugs aren’t as good as they originally thought and they needed something else?”
The reason actually is very simpleâ€¦..it’s a technology that perfectly complements our objectives. It was an opportunity too good to pass up. If ever shareholders wanted to know that they were getting value for their investment dollar, then I suggest that this deal is it.
Companies like Novogen get offered licensing opportunities on a reasonably regular basis, and if not offered, then they are floating around in the global biotech stratosphere and available if you want them badly enough.
Our R&D plate was full. We weren’t looking for anything else. We have 5 separate patent families of super-benzopyran drugs to work through, with literally tens of thousands of potential new compounds available to us to make and test if we so wanted. From the first 30 analogs we made we uncovered Trilexium and two other compounds with almost Trilexium-potency. These were compounds that for the first time in anyone’s hands were able to kill ovarian cancer stem cells and ovarian cancer somatic cells at levels not previously encountered and clinically meaningfulâ€¦.a major discovery by any standards. And if that was what we found in the first 30 compounds we looked at, then what jewels might we uncover once we trawled through thousands more of them? We didn’t need to go looking for something else to do.
google this below
Y-12 supplies the Navy with HEU from dismantled weapons to make fuel
for use in the nuclear reactors that power all U.S. submarines and aircraft carriers.
An agreement with the Department of Defense requires Y-12 to provide HEU through 2050
The ACP will be used at Y-12 is my understanding, for the production of HEU, that is something the the Silex either cannot do? or will not be allowed to do for proliferation reasons, but it (Silex laser enrichment will be a far better option for LEU compared to ACP) this is why the US are funding the development of the ACP, they want to use it at the Y-12 complex for HEU, so in effect USEC are funding 20% of the US Y-12 project, because it will not compete with laser enrichment of LEU.
The US is funding the ACP for one reason only in my opinion, the US wants a technology that is more advanced than the Gas Diffusion that USEC possessed at Pikerton and Paducah, they want ACP for their Y-12 complex, the Silex process is third generation but for proliferation reasons will never be used for HEU, that is where second generation ACP comes in, because it will be cheaper to use than first generation Gas Diffusion, to manufacture HEU, but if USEC thinks that it will be competitive for LEU then they are sadly mistaken, all they are doing by proving up the ACP technology is providing the US with the best technology for HEU, and that is why the US government is funding it, the ACP will not be able to compete with Silex laser enrichment for LEU.